Form 4: Privia Health CFO Sells Shares Under 10b5-1 Plan

David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc., reported the sale of 24,734 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc., sold 24,734 shares of common stock.
• The sale occurred on July 2, 2026, and was executed under a Rule 10b5-1 trading plan.
• The weighted average sale price was $27.50 per share, with individual transactions ranging from $27.50 to $27.51.
• Following the transaction, Mountcastle beneficially owns 186,728 shares of common stock directly.
• An additional 8,695 shares are held indirectly by his spouse.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant insider selling, despite it being executed under a Rule 10b5-1 plan. This can create negative market perception.

Negatives

• The CFO sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's future performance, although it was conducted under a pre-established trading plan.
• Market perception of insider selling can negatively impact stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transaction was executed under a Rule 10b5-1 plan, which is a pre-arranged plan for selling securities.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, is often scrutinized by investors. While these plans are designed to avoid accusations of insider trading, significant sales by executives can still influence market sentiment.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the sale with concern, potentially impacting stock price, despite the Rule 10b5-1 plan.
• Employees: May interpret the sale as a signal from management, potentially affecting morale.
• Management: The CFO is executing a pre-planned strategy for personal financial management.

Next Steps

• The reporting person will continue to hold the remaining 186,728 shares directly and 8,695 shares indirectly.
• Further transactions, if any, will be reported on subsequent SEC filings.

Key Dates

Recommendation

The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-arranged and not based on current non-public information. While insider selling can be a negative signal, the plan's existence mitigates concerns about opportunistic trading. The company's overall performance and future prospects, not detailed in this specific filing, would be the primary drivers for a buy/sell decision. Therefore, a 'hold' recommendation is appropriate pending further information.

Keywords

Privia Health Group, PRVA, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, CFO, David Mountcastle, Beneficial Ownership